investigated the recombinant oncolytic adenovirus ONCOS-102 in combination with the antibody pembrolizumab (PD-1 immune checkpoint inhibitor) in patients with locally advanced or unresectable melanoma (161). Here, PDCD1 is linked to melanoma.